Masimo Corp., of Irvine, Calif.


Noninvasive, continuous hemoglobin monitoring

Provides real-time visibility to changes to hemoglobin between invasive blood samples

Researchers at Fukuoka University in Japan evaluated whether using Masimo SpHb could help avoid postoperative anemia and inappropriate blood transfusion in patients undergoing total hip arthroplasty (THA) and total knee arthroplasty (TKA); patients undergoing THA or TKA were randomly assigned to either an SpHb-guided group (n=73) or routine care (control) group (n=72); in both groups, patients were continuously monitored using SpHb, but in the control group clinicians were blinded to the SpHb data and blood transfusion decisions were made according to traditional clinical signs such as blood loss and hemodynamic parameters; hemoglobin (Hb) was measured invasively using a laboratory hematology analyzer on the first postoperative day (POD1), with a target Hb value of ≥ 8 g/dL for all patients; researchers found that Hb on POD1 was not significantly different between the SpHb and control groups, nor was there a significant difference in blood transfusion between both groups; in the control group, 7 patients received inappropriate blood transfusion (5 excessive, 2 delayed), where excessive blood transfusion was defined as transfusion of patients with Hb > 12 g/dL and delayed blood transfusion was defined as transfusion of patients with Hb < 8 g/dL; no patients received inappropriate blood transfusion in the SpHb group (p = 0.002)


For more information about individual companies and/or products, see Cortellis.

No Comments